Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Raven Biotechnologies
company
About
Raven biotechnologies is focused on the development of monoclonal antibody therapeutics for the treatment of cancer.
- 51 - 100
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $40M
- Industries
- Biotechnology,Medical,Therapeutics
- Founded date
- Jan 1, 1999
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$88.30M
Raven Biotechnologies has raised a total of
$88.30M
in funding over 2 rounds. Their latest funding was raised on
Oct 24, 2005 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 24, 2005 | Series D | $48.30M | 3 | — | — | Detail |
| Jan 3, 2003 | Series C | $40M | 3 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
5
Raven Biotechnologies is funded by 5 investors.
Bear Stearns Health Innoventures L.P
and Milepost Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series C |
|
|
— | Series D |
|
|
— | Series D |
CIDC Consultants
|
— | Series D |
|
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
